Amyotrophic Lateral Sclerosis
Company files IND application for arimoclomol to treat ALS
Published in Obesity and Diabetes Week, June 20th, 2005
CytRx Corp. (CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics primarily in the area of small molecules and ribonucleic acid interference, announced that an investigational new drug application for arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig disease) has been filed with the U.S. Food and Drug Administration.
The company expects to initiate a phase II clinical trial for arimoclomol in June, 2005.
Jack Barber, PhD, senior vice president of drug development, said, "Arimoclomol has demonstrated neuroprotective efficacy in several preclinical animal models. We...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Body Composition
Fat mass and lean mass are highly heritable characteristics - Diabetes Pathogenesis
Maternal high-fat diet adversely affects beta-cell development - Metabolic Syndrome
Dynamic genetic architecture of metabolic syndrome attributes described - Obesity and Diabetes
Averrhoa bilimbi fractions possess anti-diabetic activity - Obesity and Diabetes
Caloric restriction modulates insulin receptor signaling in liver - Bacteriology
Biotech company offers product for removal of endotoxins - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
